Imagine a once-thriving medical technology giant, teetering on the edge of collapse. That was Convatec in 2019, a company plagued by profit warnings, a plummeting share price, and whispers of a hostile takeover. But against all odds, it rose from the ashes, thanks to the visionary leadership of Karim Bitar.
When Bitar took the helm, the FTSE 100 company was in dire straits. Former finance chief Jonny Mason recalls, “Most people thought the business should be broken up. Karim disagreed with all of that.” And this is where the story takes a remarkable turn. Bitar, who sadly passed away in October 2024, orchestrated a six-year turnaround that defied expectations.
But here’s where it gets controversial: Was Bitar’s success simply a matter of strategic brilliance, or did it hinge on his ability to inspire and connect with people on a deeper level? Mason highlights Bitar’s “strategic clarity” and talent for spotting and nurturing leaders. Yet, he also emphasizes Bitar’s personal touch, describing him as a “family man” who brought a caring dimension to the workplace. Could this human-centric approach be the secret sauce behind Convatec’s revival?
Bitar’s strategy was twofold: streamline and invest. He narrowed Convatec’s sprawling product portfolio to four core categories—advanced wound dressings, ostomy devices, urinary incontinence products, and infusion sets. This focus allowed the company to standardize operations globally, with four global presidents overseeing each category. Mason notes, “We have a vision that everyone in the organization knows.”
And this is the part most people miss: While Bitar’s initial spending spree on R&D and leadership reshuffling ate into profit margins, it laid the groundwork for long-term success. By 2024, R&D spending had more than doubled to $111 million, leading to innovative products like a device that delivers Parkinson’s medication continuously into the bloodstream. This not only improved patient outcomes but also boosted revenues.
Take, for instance, the story of a Parkinson’s patient who, thanks to Convatec’s device and a drug by AbbVie, went from being unable to make a cup of coffee to regaining control of their daily life. Stories like these underscore the impact of Bitar’s patient-centric approach.
However, Convatec’s journey isn’t without challenges. Earlier this year, the company faced scrutiny from U.S. regulators over its InnovaMatrix wound care membrane, causing a sharp drop in its share price. While InnovaMatrix accounts for just 3% of total revenue, its rapid growth made investors jittery. Is this a minor setback or a sign of deeper regulatory hurdles ahead?
Miles Dixon of Peel Hunt praises Convatec’s turnaround as a rare success in the healthcare sector, noting, “Delivering growth on public markets with a company that had lost investor trust is no small feat.” Yet, he adds, “The real test will be sustaining this momentum in a highly competitive market.”
As Convatec looks to the future, Bitar’s legacy looms large. Mason reflects, “The sadness of Karim passing immediately after achieving this is very poignant, but it’s a fabulous legacy he leaves behind.”
Here’s a thought-provoking question for you: In an era where corporate success is often measured by short-term gains, should more leaders adopt Bitar’s long-term, people-first approach? Share your thoughts in the comments—let’s spark a conversation!
